Home > Research Areas > Cancer
Cat. No. Product name CAS No.
DC10832 (E/Z)-4-hydroxy Tamoxifen Featured

(E/Z)-4-hydroxy Tamoxifen is an active metabolite of tamoxifen that is formed by the action of cytochrome P450 2D6 in human liver.

68392-35-8
DCC-073 Gossypol-acetic acid

>98%,Standard References

12542-36-8
DCF-001 Tetrandrine

>98%,Standard References

518-34-3
DCL-047 Sulforaphane

>98%,Standard References

4478-93-7
DCS-091 Cephalomannine

>98%,Standard References

71610-00-9
DCC-002 Vinblastine

>98%,Standard References

865-21-4
DC9482 17-AAG

17-AAG(NSC 330507; CP 127374) is a potent HSP90 inhibitor with IC50 of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells.

75747-14-7
DCAPI1525 5-Azacytidine

5-Azacytidine is a potent growth inhibitor and a cytotoxic agent. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (Dnmt), forming covalent adducts with cellular DNMT1 depleting enzyme activity. 5-Azacytidine also improves t

320-67-2
DC8944 5-Fluorouracil

5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.

51-21-8
DC11932 GPX-150

A doxorubicin analog that demonstrates anti-cancer activity without cardiotoxicity, does not inhibit topoisomerase IIβ activity at 100 uM.

236095-29-7
DC11861 TAK-441

A highly potent, orally active hedgehog signaling (Hh) inhibitor with IC50 of 4.4 nM in Gli-luc reporter assays.

1186231-83-3
DC11929 ME-344

A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.

1374524-68-1
DC11631 INCB040093

A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.

1262440-25-4
DC11908 Ralaniten

A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

1203490-23-6
DC11909 Ralaniten acetate

A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

1637573-02-4
DC11799 G1T38

A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

1628256-23-4
DC11800 G1T38 dihydrochloride

A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

2097938-59-3
DC11641 Cridanimod Featured

A potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.

38609-97-1
DC11710 GDC-0425

A potent, selective and orally active Chk1 inhibitor.

1200129-48-1
DC11721 PF-06747775

A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.

1776112-90-3
DC11716 XL-844

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

631864-00-1
DC11544 Onapristone

A synthetic, steroidal progesterone receptor (PR) antagonist with reduced antiglucocorticoid activity compared to mifepristone..

96346-61-1
Page 1 / Total 25 FirstPrevNextLastGoto